SFI
ALDX icon

Susquehanna Fundamental Investments’s Aldeyra Therapeutics ALDX Stock Holding History

Susquehanna Fundamental Investments’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,531
Closed -$242K – 1411
2021
Q3 		$242K Sell
27,531
-8,290
-23% -$76.1K ﹤0.01% 1476
2021
Q2 		$406K Sell
35,821
-35,810
-50% -$431K 0.01% 1245
2021
Q1 		$851K Buy
71,631
+410
+0.6% +$4.72K 0.01% 950
2020
Q4 		$489K Buy
71,221
+17,421
+32% +$122K 0.01% 1116
2020
Q3 		$399K Buy
53,800
+4,600
+9% +$29.7K 0.01% 963
2020
Q2 		$205K Buy
+49,200
New +$180K 0.01% 836

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Susquehanna Fundamental Investments's ALDX Position: Q4 2021 in Review

Susquehanna Fundamental Investments sold out of Aldeyra Therapeutics (ALDX) in Q4 2021, closing a stake of 27,531 shares — an estimated $242K sold.

Susquehanna Fundamental Investments first reported a position in ALDX in Q2 2020 and held it in 6 quarters. The position peaked at $851K in Q1 2021. 115 funds tracked by Wall St. Rank hold ALDX as of Q4 2021.

  • Susquehanna Fundamental Investments reported no remaining Aldeyra Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 27,531 Aldeyra Therapeutics shares in Q4 2021, an estimated $242K.
  • Susquehanna Fundamental Investments first reported a position in Aldeyra Therapeutics in Q2 2020 and held it in 6 quarters.
  • Susquehanna Fundamental Investments's Aldeyra Therapeutics position peaked at $851K in Q1 2021.
  • 115 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q4 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2021, filed 14 Feb 2022.